Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Press Release : Novartis: New Zolgensma data -3-

06/18/2021 | 12:30pm EDT
      May 2021. 
 
   8. Soler--Botija C, et al. Brain. 2002;125(7):1624-1634. 
 
   9. Wang CH, et al. J Child Neurol. 2007;22(8):1027-1049. 
 
  10. Darras BT, Finkel RS. "Natural history of spinal muscular atrophy." In: 
      Sumner CJ, Paushkin S, Ko CP, eds. Spinal Muscular Atrophy: Disease 
      Mechanisms and Therapy, 2nd ed. London, UK: Academic 
      Press/Elsevier;2017:399--421. 

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

 
Anja von Treskow                      Farah Bulsara Speer 
 Novartis External Communications      SVP, Corporate Communications, 
 +41 79 392 8697 (mobile)              Novartis Gene Therapies 
 anja.von_treskow@novartis.com         +1 312 543 2881 (mobile) 
 Julie Masow                           farah.speer@novartis.com 
 Novartis US External Communications 
 +1 862 579 8456 
 julie.masow@novartis.com 
 

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

 
Central                                 North America 
Samir Shah             +41 61 324 7944  Sloan Simpson  +1 862 778 5052 
Thomas Hungerbuehler   +41 61 324 8425 
Isabella Zinck         +41 61 324 7188 
 

# # #

(END) Dow Jones Newswires

June 18, 2021 12:30 ET (16:30 GMT)

All news about NOVARTIS AG
07/23NOVARTIS AG : Buy rating from UBS
MD
07/22GLOBAL MARKETS LIVE : AT&T, American Airlines, Biogen, Netflix, ABB...
07/22GLAXOSMITHKLINE : GSK appoints consumer head as CEO of new spin-off
RE
07/22NOVARTIS AG : Deutsche Bank is now Neutral
MD
07/22ANALYST RECOMMENDATIONS : Barclays, Chevron, Flutter, Netflix, Unilever...
07/22NOVARTIS AG : Credit Suisse sticks Neutral
MD
07/22NOVARTIS : ESG Update - July 22, 2021
PU
07/22NOVARTIS AG : Goldman Sachs remains its Buy rating
MD
07/21NOVARTIS AG : Bernstein sticks Neutral
MD
07/21European Stocks Close in Green On Strong Earnings
MT
More news
Financials (USD)
Sales 2021 51 952 M - -
Net income 2021 9 789 M - -
Net Debt 2021 24 191 M - -
P/E ratio 2021 20,1x
Yield 2021 3,56%
Capitalization 224 B 224 B -
EV / Sales 2021 4,77x
EV / Sales 2022 4,44x
Nbr of Employees 109 000
Free-Float 87,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 91,89 $
Average target price 105,25 $
Spread / Average Target 14,5%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG1.10%207 246
JOHNSON & JOHNSON9.16%432 430
ROCHE HOLDING AG12.39%325 975
PFIZER, INC.13.23%218 198
ELI LILLY AND COMPANY44.60%209 276
ABBVIE INC.10.30%199 548